<DOC>
	<DOCNO>NCT00663117</DOCNO>
	<brief_summary>It hypothesize opioid antagonist naltrexone improve inflammation bowel quality life subject active Crohn 's disease compare placebo . In order test hypothesis follow specific aim propose : 1 . Evaluate effect low dose naltrexone compare placebo activity Crohn 's disease follow end point : Crohn 's Disease Activity Index ( CDAI ) , pain assessment , laboratory value ( CRP ESR ) , endoscopic appearance , histology , quality life survey ; 2 . Examine effect naltrexone give 3 month compare 6 month durability response ; 3 . Determine safety toxicity low dose naltrexone subject active Crohn 's disease , 4 . Study mechanism naltrexone exert effect measure plasma enkephalin level subject therapy . Purpose statement : The purpose study evaluate effect low dose naltrexone blind placebo control study determine safety efficacy compound active Crohn 's disease .</brief_summary>
	<brief_title>The Effects Naltrexone Active Crohn 's Disease</brief_title>
	<detailed_description>Study design : The study design double-blind placebo control study 3 month follow pseudo cross-over subject receive placebo first 3 month receive active drug second 3 month receive naltrexone first 3 month remain drug last 3 month 6 month study .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>All subject must give write informed consent Male female subject , &gt; 18 year Patients must endoscopic , histologic , radiographic confirm Crohn 's Disease . Patients must Crohn 's Disease Activity Index ( CDAI ) least 220 Baseline Stable dos medication Crohn 's disease proceed 4 week ( aminosalicylates steroid : prednisone 10mg less daily Entocort 3 mg/ day allow ) , 12 week azathioprine 6mercaptopurine . ) Subjects ostomies ileorectal anastomosis prior surgical colectomy . Subjects receive infliximab ( Remicade ) within 8 week study screen humira 4 week . Subjects require steroid either intravenously prednisone &gt; 10mg /day Entocort &gt; 3 mg daily . Subjects shortbowel syndrome . Abnormal liver enzymes screening visit know hepatitis cirrhosis Hemoglobin le 10 . Subjects cancer ( skin cancer ) past 5 year . Women childbearing potential unless surgically sterile use adequate contraception ( either IUD , oral deport contraceptive , barrier plus spermicide ) , willing able continue contraception 3 month completion study . Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>naltrexone</keyword>
	<keyword>LDN</keyword>
	<keyword>IBD</keyword>
	<keyword>Inflammatory bowel disease</keyword>
</DOC>